ed future earnings , there is a reasonable possibility that we will have 
sufficient evidence to release a significant portion of the valua tion allowance in the Netherlands within the next 12 months. H owever, 
our judgment regarding future earnings and the exact timing and am ount of any valuation allowance release are subject to change  due 
to many factors, including future market conditions and the abili ty to successfully execute our business plans and/or tax plann ing  
116 
strategies. Release of the valuation allowance would result in th e recognition of net deferred tax assets on our consolidated b alance 
sheet and would result in an income tax benefit in the period the release is recorded. 
As of December 31, 2024, we had U.S. federal NOL carryforwar ds of $176 million that begin to  expire in 2031 and $8.2 billion 
that have an unlimited carryover period. As  of December 31, 2024, we had U.S. stat e NOL carryforwards of $7.5 billion that star ted 
expiring in 2024 and $1.6 billion th at have an unlimited carryove r period. As of December 31, 2024, we had foreign NOL 
carryforwards of $759 million that begin to expire in 2024 and $19.2 billion that have an unlimited carryover period. 
As of December 31, 2024, we ha d U.S. federal research tax cred it carryforwards of $1.2 billion th at begin to expire in 2028. We  
had U.S. state research tax credit carryforwards of $798 million that have an unlimited carryover period.